Literature DB >> 24925589

Pulmonary, renal and neurological comorbidities in patients with ankylosing spondylitis; implications for clinical practice.

Cecilia Mercieca1, Irene E van der Horst-Bruinsma, Andrew A Borg.   

Abstract

Ankylosing spondylitis (AS) is associated with several comorbidities which contribute significantly to morbidity and mortality and add to the complexity of management. In addition to the well known extra-articular manifestations and increased cardiovascular risk, several pulmonary, renal, and neurological complications which have been associated with AS deserve equal attention. Whereas a clear link has been established for some manifestations, the evidence for other associations is less clear. Interstitial lung disease, apical fibrosis, secondary infection, and ventilatory restriction from reduced chest wall movement are well known pulmonary complications; more recently an association with sleep apnoea has been suggested. Renal amyloidosis and IgA nephropathy remain a treatment challenge which may respond to anti-TNF therapy. Atlanto axial subluxation and vertebral fractures can result in serious neurological complications and are notoriously difficult to diagnose unless a high level of suspicion is maintained. Despite several reports linking AS with demyelination a true link remains to be proved. This review discusses the prevalence, pathophysiology, and management of pulmonary, renal, and neurological complications, and implications for clinical practice.

Entities:  

Mesh:

Year:  2014        PMID: 24925589     DOI: 10.1007/s11926-014-0434-7

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  109 in total

1.  Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis.

Authors:  S D Yan; H Zhu; A Zhu; A Golabek; H Du; A Roher; J Yu; C Soto; A M Schmidt; D Stern; M Kindy
Journal:  Nat Med       Date:  2000-06       Impact factor: 53.440

2.  Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.

Authors:  Antonio Fernández-Nebro; Eva Tomero; Vera Ortiz-Santamaría; María Carmen Castro; Alejandro Olivé; Manuel de Haro; Rosa García Portales; Rosa García-Vicuña; María Victoria González-Mari; Armando Laffón; Rosario García-Vicuña
Journal:  Am J Med       Date:  2005-05       Impact factor: 4.965

Review 3.  Pleuropulmonary involvement in ankylosing spondylitis.

Authors:  Abdellah El Maghraoui
Journal:  Joint Bone Spine       Date:  2005-12       Impact factor: 4.929

4.  Prevalence and risk factors of anterior atlantoaxial subluxation in ankylosing spondylitis.

Authors:  Ji-Seon Lee; Seunghun Lee; So-Young Bang; Kyung Soo Choi; Kyung Bin Joo; Yong-Bum Kim; I L-Hoon Sung; Tae-Hwan Kim
Journal:  J Rheumatol       Date:  2012-10-01       Impact factor: 4.666

Review 5.  Demyelination and inhibition of tumor necrosis factor (TNF).

Authors:  M D Magnano; W H Robinson; M C Genovese
Journal:  Clin Exp Rheumatol       Date:  2004 Sep-Oct       Impact factor: 4.473

6.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; J Listing; N Akkoc; J Brandt; J Braun; C T Chou; E Collantes-Estevez; M Dougados; F Huang; J Gu; M A Khan; Y Kirazli; W P Maksymowych; H Mielants; I J Sørensen; S Ozgocmen; E Roussou; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2009-03-17       Impact factor: 19.103

7.  Lower frequency of obstructive sleep apnea in spondyloarthritis patients taking TNF-inhibitors.

Authors:  Jessica A Walsh; Kristina Callis Duffin; Julia Crim; Daniel O Clegg
Journal:  J Clin Sleep Med       Date:  2012-12-15       Impact factor: 4.062

8.  Occurrence of ankylosing spondylitis and multiple sclerosis-like syndrome in a HLA-B27 positive patient.

Authors:  Andrea Mignarri; Maria Teresa Dotti; Carla Battisti; Ignazio Vallone; Antonio Federico
Journal:  Neurol Sci       Date:  2009-05-15       Impact factor: 3.307

Review 9.  Cytokines and pathological sleep.

Authors:  Fotis Kapsimalis; Maria Basta; George Varouchakis; Konstantinos Gourgoulianis; Alexandros Vgontzas; Meir Kryger
Journal:  Sleep Med       Date:  2007-11-19       Impact factor: 3.492

10.  Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker.

Authors:  Sang-Hoon Lee; Eun Jung Lee; Sang Wan Chung; Ran Song; Joo-Young Moon; Sang-Ho Lee; Sung-Jig Lim; Yeon-Ah Lee; Seung-Jae Hong; Hyung-In Yang
Journal:  Rheumatol Int       Date:  2012-12-27       Impact factor: 2.631

View more
  16 in total

1.  The risk of asthma in patients with ankylosing spondylitis: a population-based cohort study.

Authors:  Te-Chun Shen; Cheng-Li Lin; Chang-Ching Wei; Chia-Hung Chen; Chih-Yen Tu; Te-Chun Hsia; Chuen-Ming Shih; Wu-Huei Hsu; Fung-Chang Sung
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

2.  Axial Spondyloarthritis and Autosomal Dominant Polycystic Kidney Disease in Two Siblings: A Rare Cooccurrence.

Authors:  Ozan Volkan Yurdakul; Abdulkerim Furkan Tamer; Okan Küçükakkaş; Aylin Rezvani
Journal:  Case Rep Rheumatol       Date:  2018-03-04

Review 3.  Patient Burden of Axial Spondyloarthritis.

Authors:  Vibeke Strand; Jasvinder A Singh
Journal:  J Clin Rheumatol       Date:  2017-10       Impact factor: 3.517

4.  Healthcare Utilization and Direct Costs in Patients with Ankylosing Spondylitis Using a Large US Administrative Claims Database.

Authors:  Jessica A Walsh; Xue Song; Gilwan Kim; Yujin Park
Journal:  Rheumatol Ther       Date:  2018-08-18

5.  Pulmonary high-resolution computed tomography findings in patients with synovitis, acne, pustulosis, hyperostosis and osteitis syndrome.

Authors:  Chen Li; Shuang Liu; Xin Sui; Jian Wang; Wei Song; Wenshuai Xu; Kai-Feng Xu; Xinlun Tian; Wen Zhang
Journal:  PLoS One       Date:  2018-12-05       Impact factor: 3.240

Review 6.  A meta-analysis for association of TNF-α -308G>A polymorphism with susceptibility to Ankylosing Spondylitis.

Authors:  Masoud Mahdinejad-Yazdi; Mohammad Reza Sobhan; Seyed Alireza Dastgheib; Reza Bahrami; Seyed Hossein Shaker; Hamid Mirjalili; Jalal Sadeghizadeh-Yazdi; Masoud Zare-Shehneh; Hossein Neamatzadeh
Journal:  J Orthop       Date:  2021-07-14

7.  Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set.

Authors:  Jessica A Walsh; Xue Song; Gilwan Kim; Yujin Park
Journal:  J Pharm Health Serv Res       Date:  2018-01-16

8.  Anti-citrullinated protein antibody response after primary EBV infection in kidney transplant patients.

Authors:  Lianne J N Kraal; Marieke L Nijland; Kristine L Germar; Dominique L P Baeten; Ineke J M Ten Berge; Cynthia M Fehres
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

9.  Membranous nephropathy and thymoma in a patient with ankylosing spondylitis: A case report.

Authors:  Lirong Lin; Lei Zhao; Bengang Huo; Luquan Zheng; Rongjie Yu; Weibing Li; Jurong Yang
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.817

10.  Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry.

Authors:  Philip J Mease; Désirée van der Heijde; Chitra Karki; Mei Liu; Yujin Park; Jeffrey D Greenberg
Journal:  Rheumatol Ther       Date:  2018-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.